全文获取类型
收费全文 | 1720744篇 |
免费 | 125816篇 |
国内免费 | 5622篇 |
专业分类
耳鼻咽喉 | 21887篇 |
儿科学 | 55951篇 |
妇产科学 | 46500篇 |
基础医学 | 244185篇 |
口腔科学 | 49184篇 |
临床医学 | 154772篇 |
内科学 | 337485篇 |
皮肤病学 | 38874篇 |
神经病学 | 132608篇 |
特种医学 | 64725篇 |
外国民族医学 | 263篇 |
外科学 | 259720篇 |
综合类 | 42994篇 |
现状与发展 | 9篇 |
一般理论 | 532篇 |
预防医学 | 126137篇 |
眼科学 | 40831篇 |
药学 | 126187篇 |
30篇 | |
中国医学 | 5870篇 |
肿瘤学 | 103438篇 |
出版年
2021年 | 14256篇 |
2019年 | 14458篇 |
2018年 | 20918篇 |
2017年 | 16126篇 |
2016年 | 17401篇 |
2015年 | 20184篇 |
2014年 | 27650篇 |
2013年 | 39246篇 |
2012年 | 54612篇 |
2011年 | 57533篇 |
2010年 | 33986篇 |
2009年 | 31636篇 |
2008年 | 52821篇 |
2007年 | 56006篇 |
2006年 | 56481篇 |
2005年 | 53769篇 |
2004年 | 51597篇 |
2003年 | 48832篇 |
2002年 | 47027篇 |
2001年 | 92225篇 |
2000年 | 94098篇 |
1999年 | 77554篇 |
1998年 | 20109篇 |
1997年 | 17648篇 |
1996年 | 17680篇 |
1995年 | 16998篇 |
1994年 | 15479篇 |
1993年 | 14219篇 |
1992年 | 57569篇 |
1991年 | 55409篇 |
1990年 | 53105篇 |
1989年 | 50862篇 |
1988年 | 46239篇 |
1987年 | 45024篇 |
1986年 | 42309篇 |
1985年 | 40067篇 |
1984年 | 29375篇 |
1983年 | 24932篇 |
1982年 | 13912篇 |
1979年 | 25543篇 |
1978年 | 17580篇 |
1977年 | 14907篇 |
1976年 | 13877篇 |
1975年 | 14566篇 |
1974年 | 17634篇 |
1973年 | 16944篇 |
1972年 | 15676篇 |
1971年 | 14460篇 |
1970年 | 13438篇 |
1969年 | 12519篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
42.
Sundaram Kavin Piuzzi Nicolas S. Patterson Brendan M. Stearns Kim L. Krebs Viktor E. Mont Michael A. 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2020,30(3):447-453
European Journal of Orthopaedic Surgery & Traumatology - The goals of this study were to compare patient satisfaction and wound-related complications in patients receiving 2-octyl cyanoacrylate... 相似文献
43.
44.
文题释义:股骨头坏死中日友好医院分型的有限元分析:根据李子荣等提出的中日友好医院分型,建立股骨头坏死三维模型,分为 M型(内侧型)、C型(中央型)和 L型(外侧型),其中 L型包括L1型(次外侧型)、L2型(极外侧型)和 L3型(全头型)。通过对建立的模型进行有限元分析,为该分型的保髋治疗提供了一定力学依据,显示外侧柱的存留是精准预防塌陷的重要因素,为进一步实现个体化治疗提供力学基础。
腓骨支撑坏死股骨头保髋手术:是对于早中期股骨头坏死需要保留股骨头患者进行的一种手术方式。首先需对股骨头进行髓芯减压,清除一定坏死骨,空腔填塞松质骨(髂骨为主),打压结实后植入腓骨(异体或自体)支撑,给坏死区的提供力学支撑及生物学修复,预防股骨头进一步坏死及塌陷。
背景:研究报道股骨头坏死的保髋疗效与外侧柱存留密切相关,中日友好医院分型是根据三柱结构确立的,对股骨头塌陷的预测准确性高。
目的:建立股骨头坏死中日友好医院分型各分型仿真的三维有限元模型,通过有限元分析各分型腓骨植入的力学变化,探讨外侧柱存留对保髋疗效的意义,为该分型的塌陷精准预测提供基础。
方法:建立正常股骨头、中日友好医院分型(M型、C型、L1型、L2型、L3型)股骨头坏死及其腓骨植入3组11种三维有限元模型,运用ANSYS软件进行有限元分析计算,观察各组模型的最大应力值、最大位移值及股骨头内部载荷传递模式。
结果与结论:①坏死组位移最大,应变最大,且因坏死分型不同而位移不同,位移变化如下:M型相似文献
45.
Methicillin‐resistant Staphylococcus aureus eradication in young infants should include the diaper area and treat housing contacts
下载免费PDF全文
![点击此处可从《Acta paediatrica (Oslo, Norway : 1992)》网站下载免费的PDF全文](/ch/ext_images/free.gif)
46.
M. R. D. Maslin S. K. Lloyd S. Rutherford S. Freeman A. King D. R. Moore K. J. Munro 《Journal of the Association for Research in Otolaryngology》2015,16(5):631-640
Individuals with sudden unilateral deafness offer a unique opportunity to study plasticity of the binaural auditory system in adult humans. Stimulation of the intact ear results in increased activity in the auditory cortex. However, there are no reports of changes at sub-cortical levels in humans. Therefore, the aim of the present study was to investigate changes in sub-cortical activity immediately before and after the onset of surgically induced unilateral deafness in adult humans. Click-evoked auditory brainstem responses (ABRs) to stimulation of the healthy ear were recorded from ten adults during the course of translabyrinthine surgery for the removal of a unilateral acoustic neuroma. This surgical technique always results in abrupt deafferentation of the affected ear. The results revealed a rapid (within minutes) reduction in latency of wave V (mean pre = 6.55 ms; mean post = 6.15 ms; p < 0.001). A latency reduction was also observed for wave III (mean pre = 4.40 ms; mean post = 4.13 ms; p < 0.001). These reductions in response latency are consistent with functional changes including disinhibition or/and more rapid intra-cellular signalling affecting binaurally sensitive neurons in the central auditory system. The results are highly relevant for improved understanding of putative physiological mechanisms underlying perceptual disorders such as tinnitus and hyperacusis. 相似文献
47.
Benyam Kinde Harrison W. Gabel Caitlin S. Gilbert Eric C. Griffith Michael E. Greenberg 《Proceedings of the National Academy of Sciences of the United States of America》2015,112(22):6800-6806
DNA methylation at CpG dinucleotides is an important epigenetic regulator common to virtually all mammalian cell types, but recent evidence indicates that during early postnatal development neuronal genomes also accumulate uniquely high levels of two alternative forms of methylation, non-CpG methylation and hydroxymethylation. Here we discuss the distinct landscape of DNA methylation in neurons, how it is established, and how it might affect the binding and function of protein readers of DNA methylation. We review studies of one critical reader of DNA methylation in the brain, the Rett syndrome protein methyl CpG-binding protein 2 (MeCP2), and discuss how differential binding affinity of MeCP2 for non-CpG and hydroxymethylation may affect the function of this methyl-binding protein in the nervous system. 相似文献
48.
49.
Edward J. Holland Walter O. Whitley Kenneth Sall Stephen S. Lane Aparna Raychaudhuri Steven Y. Zhang 《Current medical research and opinion》2016,32(10):1759-1765
Objective: Report efficacy findings from three clinical trials (one phase 2 and two phase 3 [OPUS-1, OPUS-2]) of lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease (DED).Research design and methods: Three 84-day, randomized, double-masked, placebo-controlled trials. Adults (≥18 years) with DED were randomized (1:1) to lifitegrast 5.0% or matching placebo. Changes from baseline to day 84 in signs and symptoms of DED were analyzed.Main outcome measures: Phase 2, pre-specified endpoint: inferior corneal staining score (ICSS; 0–4); OPUS-1, coprimary endpoints: ICSS and visual-related function subscale (0–4 scale); OPUS-2, coprimary endpoints: ICSS and eye dryness score (EDS, VAS; 0–100).Results: Fifty-eight participants were randomized to lifitegrast 5.0% and 58 to placebo in the phase 2 trial; 293 to lifitegrast and 295 to placebo in OPUS-1; 358 to lifitegrast and 360 to placebo in OPUS-2. In participants with mild-to-moderate baseline DED symptomatology, lifitegrast improved ICSS versus placebo in the phase 2 study (treatment effect, 0.35; 95% CI, 0.05–0.65; p?=?0.0209) and OPUS-1 (effect, 0.24; 95% CI, 0.10–0.38; p?=?0.0007). Among more symptomatic participants (baseline EDS ≥40, recent artificial tear use), lifitegrast improved EDS versus placebo in a post hoc analysis of OPUS-1 (effect, 13.34; 95% CI, 2.35–24.33; nominal p?=?0.0178) and in OPUS-2 (effect, 12.61; 95% CI, 8.51–16.70; p?<?0.0001).Limitations: Trials were conducted over 12 weeks; efficacy beyond this period was not assessed.Conclusions: Across three trials, lifitegrast improved ICSS in participants with mild-to-moderate baseline symptomatology in two studies, and EDS in participants with moderate-to-severe baseline symptomatology in two studies. Based on the overall findings from these trials, lifitegrast shows promise as a new treatment option for signs and symptoms of DED. 相似文献
50.